These results suggest that elevated C4S expression correlates with platinum resistance in ovarian cancer, highlighting C4S as a potential biomarker for predicting chemoresistance and a targetable feature for therapeutic intervention. The gene discussed is C4A; the disease is ovarian carcinoma.